BioWorld

Feb. 10, 2006

View Archived Issues

Elan Sells European Prialt Rights To Eisai For $100M

Elan Corp. plc decided to sell the European rights to its pain product Prialt, but is keeping U.S. rights, where the drug already is being sold. (BioWorld Today) Read More

Inflabloc Adds Cancer Drugs Through Merger, Raises $6M

Read More

Diversified Risk Important To Investors In Stem Cells

Read More

Series A Now Done, Proacta Has Funds To Fight Tumors

Read More

Other News To Note

Read More

Clinic Roundup

Read More